Successful treatment of angiosarcoma of the scalp with apatinib: a case report

Ji, Guangyong; Liu, Hong; Yang, Ping

doi:10.2147/ott.s110235

Cited by 29 publications

(25 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 A case of 74-y-old angiosarcoma patient was confirmed with local tumor recurrence with multiple metastases. 8 His PFS time was as long as 12 months. An 18-y-old alveolar soft part sarcoma case with multiple lung metastases achieved a PR and a PFS of 12 months after Figure 1.…”

Section: Discussionmentioning

confidence: 99%

“…Promising efficacy of apatinib was reported in several subtypes of sarcomas. [6][7][8][9][10] We further retrospectively investigated the outcomes of apatinib in 31 patients with advanced metastatic or recurrent sarcoma who pretreated with at least one chemotherapy regimen or refused to receive chemotherapy. in 7 patients (22.6%) and trunk in 3 patients (9.7%).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Zhu

Xie

et al. 2018

Cancer Biology & Therapy

View full text Add to dashboard Cite

Sarcomas are rare but malignant tumors with high risks of local recurrence and distant metastasis. Anti-angiogenic therapy is a potential strategy against un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety and efficacy of apatinib, an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, in patients with advanced sarcoma. Thirty-one patients who received initial apatinib between September 2015 and August 2016 were retrospectively reviewed. Among them, 19 (61.3%) patients were heavily pretreated with two or more lines of cytotoxic chemotherapy. Apatinib was given at a start-dose of 425 mg qd. During therapy, 9 (29.0%) patients required dose interruption and 7 (22.6%) needed dose reduction, and the mean dosage of apatinib was 372.9 ± 68.4 mg/day. In the study cohort, one patient was treated as adjunctive therapy and 6 patients stopped treatment before radiographic response assessment. Thus, 24 patients were eligible for tumor response evaluation. The objective response rate was 33.3% and clinical benefit rate was as high as 75.0%. The progression free survival was 4.25 (95% confidence interval [CI], 2.22-5.11) months, whereas the overall survival was 9.43 (95% CI, 6.64-18.72) months. Compared with other histological subtypes, leiomyosarcoma did not show significant survival benefits. Most of the adverse events (AEs) were at grade 1 or 2. The main grade 3 AEs were hypertension (6.5%), hand foot skin reaction (6.5%), and diarrhea (3.2%). In conclusion, apatinib showed promising efficacy and acceptable safety profile in metastatic or recurrent sarcoma, giving rationale clinical evidence to conduct clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Zhu

Xie

et al. 2018

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Angiosarcoma is a rare aggressive malignant tumor of vascular endothelial cells, the face and scalp regions account for more than 50% of cutaneous angiosarcomas. Surgery could be the most effective method of treatment, but for advanced and metastatic angiosarcoma, chemotherapy would be the main choice . However, adjuvant postoperative radiotherapy improves the outcome …”

Section: Discussionmentioning

confidence: 99%

Scalp ulcers – differential diagnoses that should be sought!

2019

View full text Add to dashboard Cite

Background Ulceration of the scalp is an uncommon clinical presentation, and it may be caused by myriads of cutaneous etiologies such as infections, inflammatory disorders, and malignancies. We sought to reveal the underlying etiology of scalp ulcers referred to our tertiary wound healing clinic; we would also like to propose a classification for scalp ulcerations.Methods A retrospective study was conducted in an academic tertiary wound healing clinic between January 2015 and June 2018. The study was approved by the Women's College Hospital Institutional Research Ethics Board. We have also conducted a review of the literature to recognize the major causes of scalp ulceration reported in the literature. ResultsWe have identified a total number of 15 patients with scalp ulceration. Twelve patients with atypical scalp ulcers underwent a skin biopsy. A malignancy rate of 73% (11/ 15) was diagnosed histologically. The review of the literature showed 237 articles. After screening the title and the abstracts, we have selected 41 case reports for the full text review.Conclusion Scalp ulcers are uncommon but important. Our sample study indicates the high frequency of malignant etiologies presenting as scalp ulcers. These results emphasize not only the need for clinicians to be on the watch for the possibility of this option but rather highlights the need for early biopsy to prevent further complications. We hope that our paper helps to shed some light on this topic and guide clinicians on how to approach scalp ulceration.

show abstract

“…Furthermore, it has been reported that positive immunohistochemical staining for VEGF occurs in 14% of primary angiosarcomas and of its 3 known receptors, VEGFR3 has been shown to be present in 50% of all angiosarcomas (5). Given the potential involvement of these signalling pathways in the pathogenesis of post-radiotherapy angiosarcoma, it seems reasonable to consider the use of VEGF antagonists such as bevacizumab (humanized monoclonal antibody targeting VEGF-A), sorafenib (an inhibitor of VEGFR1, VEGFR2, VEGRF3 among other receptors) (15), pazopanib (an inhibitor of VEGF2 and VEGF3) (16,17), apatinib (an inhibitor of VEGF2) (18) or even thalidomide (known to suppress VEGF) (19) in the treatment of angiosarcoma.…”

Section: Discussionmentioning

confidence: 99%

A radiation-induced and radiation-sensitive, delayed onset angiosarcoma arising in a precursor lymphangioendothelioma

et al. 2017

View full text Add to dashboard Cite

An 83-year-old female was treated with mastectomy and postoperative radiotherapy for breast cancer 30 years prior to developing a new small patch of thickening and scaliness on her left upper back, within the previous radiotherapy field. Serial excision biopsies revealed this to be a lymphangioendothelioma with no suggestion of malignancy. In early 2006 the lesion began to enlarge and take on a more erythematous plaque-like appearance. She was reviewed by a specialist dermatologist and an excision biopsy revealed a low-grade cutaneous angiosarcoma; this was approximately 38 years after radiotherapy to this region, the longest reported period between irradiation and in-field angiosarcoma development (the previous being 16 years). To our knowledge, this is the first case of post-radiotherapy angiosarcoma with a diagnosed precursor lesion. The lesion was treated with surgical excision and adjuvant radiotherapy. After further in-and out of-field recurrences, low dose radiotherapy elicited a surprisingly rapid and complete response within the treated areas; this was unusual in that these tumours are characteristically radiation-resistant. The radiosensitive case we report here raises the possibility that radiation should be more widely considered in the therapy of this disease. Methods of treatment of this rare malignancy are discussed.

show abstract

Successful treatment of angiosarcoma of the scalp with apatinib: a case report

Cited by 29 publications

References 10 publications

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Scalp ulcers – differential diagnoses that should be sought!

A radiation-induced and radiation-sensitive, delayed onset angiosarcoma arising in a precursor lymphangioendothelioma

Contact Info

Product

Resources

About